The biology behind the new therapies for SLE

International Journal of Clinical Practice

Volumn 61, Issue 12, 2007, Pages 2113-2119

  Ermann, J ^a   Bermas, B L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; AUTOANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOKINE; HYDROXYCHLOROQUINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TOLL LIKE RECEPTOR;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; DISEASE COURSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; IMMUNE DYSREGULATION; IMMUNE SYSTEM; LUPUS ERYTHEMATOSUS NEPHRITIS; MORBIDITY; MORTALITY; NEUROPSYCHIATRY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, MONOCLONAL; ANTIGENS; AUTOANTIBODIES; B-LYMPHOCYTES; CYTOKINES; HUMANS; HYDROXYCHLOROQUINE; IMMUNITY, CELLULAR; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MYCOPHENOLIC ACID; OLIGONUCLEOTIDES; TOLL-LIKE RECEPTORS;

EID: 35948981101     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01528.x     Document Type: Review

References (60)

1. Shee JC. Lupus erythematosus treated with chloroquine. Lancet 1953 265 : 201 2.
2. Munoz LE, Gaipl US, Franz S et al. SLE - a disease of clearance deficiency Rheumatology (Oxford) 2005 44 : 1101 7.
3. Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995 374 : 546 9.
4. Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000 408 : 740 5.
5. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004 5 : 987 95.
6. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006 6 : 823 35.
7. Sigurdsson S, Nordmark G, Goring HH et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 2005 76 : 528 37.
8. Graham RR, Kozyrev SV, Baechler EC et al. (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006 38 : 550 5.
9. Leadbetter EA, Rifkin IR, Hohlbaum AM et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002 416 : 603 7.
10. Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006 25 : 383 92.
11. Ronnblom LE, Alm GV, Oberg K. Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol 1991 30 : 537 40.
12. Bennett L, Palucka AK, Arce E et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003 197 : 711 23.
13. Baechler EC, Batliwalla FM, Karypis G et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003 100 : 2610 5.
14. Siegal FP, Kadowaki N, Shodell M et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999 284 : 1835 7.
15. Blanco P, Palucka AK, Gill M et al. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001 294 : 1540 3.
16. Farkas L, Beiske K, Lund-Johansen F et al. Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001 159 : 237 43.
17. Kolumam GA, Thomas S, Thompson LJ et al. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 2005 202 : 637 50.
18. Jego G, Palucka AK, Blanck JP et al. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6 Immunity. Immunity 2003 19 : 225 34.
19. Liu K, Mohan C. What do mouse models teach us about human SLE Clin Immunol 2006 119 : 123 30.
20. Lee YH, Rho YH, Choi SJ et al. The PTPN22 C1858T functional polymorphism and autoimmune diseases - a meta-analysis. Rheumatology (Oxford) 2007 46 : 49 56.
21. Tsao BP, Ohnishi K, Cheroutre H et al. Failed self-tolerance and autoimmunity in IgG anti-DNA transgenic mice. J Immunol 1992 149 : 350 8.
22. Katz JB, Limpanasithikul W, Diamond B. Mutational analysis of an autoantibody: differential binding and pathogenicity. J Exp Med 1994 180 : 925 32.
23. DeGiorgio LA, Konstantinov KN, Lee SC et al. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001 7 : 1189 93.
24. Hanly JG, Robichaud J, Fisk JD. Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. J Rheumatol 2006 33 : 1553 8.
25. Lapteva L, Nowak M, Yarboro CH et al. Anti-N-methyl-d-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum 2006 54 : 2505 14.
26. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999 42 : 599 608.
27. Arbuckle MR, McClain MT, Rubertone MV et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003 349 : 1526 33.
28. Tsakonas E, Joseph L, Esdaile JM et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998 7 : 80 5.
29. Molad Y, Gorshtein A, Wysenbeek AJ et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus 2002 11 : 356 61.
30. Fessler BJ, Alarcon GS, McGwin G Jr. et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005 52 : 1473 80.
31. Kasitanon N, Fine DM, Haas M et al. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 2006 15 : 366 70.
32. Marmor MF, Carr RE, Easterbrook M et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002 109 : 1377 82.
33. Edwards JC, Cambridge G, Leandro MJ. B cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheumatol 2006 20 : 915 28.
34. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006 54 : 1390 400.
35. Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006 54 : 2793 806.
36. Perrotta S, Locatelli F, La Manna A et al. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol 2002 116 : 465 7.
37. Smith KG, Jones RB, Burns SM et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006 54 : 2970 82.
38. van Vollenhoven RF, Gunnarsson I, Welin-Henriksson E et al. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand J Rheumatol 2004 33 : 423 7.
39. Sfikakis PP, Boletis JN, Lionaki S et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005 52 : 501 13.
40. Tokunaga M, Saito K, Kawabata D et al. Efficacy of rituximab (Anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007 66 : 470 5.
41. Eisenberg R, Albert D. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol 2006 2 : 20 7.
42. Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease-the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 2007 3 : 86 95.
43. Langer-Gould A, Steinman L. What went wrong in the natalizumab trials Lancet 2006 367 : 708 10.
44. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005 80 : S181 90.
45. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005 353 : 2219 28.
46. Chan TM, Li FK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000 343 : 1156 62.
47. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004 350 : 971 80.
48. Chan TM, Tse KC, Tang CS et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005 16 : 1076 84.
49. Petri M. Cyclophosphamide: new approaches for systemic lupus erythematosus. Lupus 2004 13 : 366 71.
50. Dooley MA. Mycophenylate mofetil: what role in the treatment of lupus Lupus 2006 15 : 179 82.
51. De Angelis C, Drazen JM, Frizelle FA et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med 2004 351 : 1250 1.
52. Aringer M, Graninger WB, Steiner G et al. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004 50 : 3161 9.
53. Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004 13 : 339 43.
54. Treml LS, Crowley JE, Cancro MP. BLyS receptor signatures resolve homeostatically independent compartments among naive and antigen-experienced B cells. Semin Immunol 2006 18 : 297 304.
55. Stohl W, Looney RJ. B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks Clin Immunol 2006 121 : 1 12.
56. Todd DJ, Costenbader KH, Weinblatt ME. Abatacept in the treatment of rheumatoid arthritis. Int J Clin Pract 2007 61 : 494 500.
57. Cunnane G, Chan OT, Cassafer G et al. Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide. Arthritis Rheum 2004 50 : 1539 48.
58. Alarcon-Segovia D, Tumlin JA, Furie RA et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003 48 : 442 54.
59. Luger D, Dayan M, Zinger H et al. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J Clin Immunol 2004 24 : 579 90.
60. Burt RK, Marmont A, Oyama Y et al. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum 2006 54 : 3750 60.